The raising, which represents two-thirds of the biotech’s existing market value, is priced a $1.50 a share, or a 6.3 per cent discount to Friday’s closing price.
Sean Smith
WA-based Little Green Pharma has announced a proposed merger with a fellow Victorian medicinal cannabis company in a bid to create a powerhouse in the global weed industry.
Cheyanne Enciso
WA telehealth startup BlinkLab reckons it has the answer to solving Perth’s paediatrician crisis that has left children with developmental and behavioural issues waiting years for help.
Peter Coleman will take over from Alan Tribe next week, two months after embarrassing infighting that saw PYC’s managing director resign and then return five days later.
The Melbourne-based blood-products company plans to cut $500 million in costs in response to slowing sales growth. Here is what’s behind the drop.
Aaron Patrick
The funds will also support the purchase of a 15 per cent stake in fellow WA biotech, the unlisted Marine Biomedical, and a clinical study into the use of Remplir in prostate cancer surgery.
Managing director Rohan Hockings has finally come clean over last month’s extraordinary leadership implosion.
Using psychedelics to treat mental health conditions like post-traumatic stress disorder and depression has been divisive and shrouded in secrecy, but patients say the results speak for themselves.
PYC Therapeutics’ reappointed chief has assured nervous investors a new-look board is now ‘very aligned’ on the company’s direction following his shock return less than a week after he abruptly quit.
Australia’s biggest health insurer is expanding its landmark deal with WA biotech Emyria by announcing it will also fund the use of psilocybin to treat treatment-resistant depression.
PYC Therapeutics has entered a trading halt just days after its long-servingboss abruptly quit, with the biotech’s 77-year-old chair taking the reins.
PYC Therapeutics’ 77-year-old chair Alan Tribe will take on the day-to-day management of the biotech where he is the biggest shareholder after long-serving boss Rohan Hockings abruptly resigned.
Australian urologists are now using Orthocell’s flagship nerve repair product during prostate cancer surgery in what the WA biotech says has potential to reduce the risks of erectile dysfunction.
CSL is paying to partner with a Dutch company developing an emergency treatment for patients on blood thinners who experience uncontrolled bleeding.
Derek Rose
Biotech giant CSL is set to axe almost 3000 jobs globally as it announces a major restructure and savings drive that will see its flu vaccine arm spun off into a separately listed company.
WA biotech Emyria will deliver its MDMA-based therapy aimed at treating post-traumatic stress disorder to Brisbane patients after inking a deal with a national mental health hospital operator.
WA biotech Emyria says it’s in talks with other major Australian insurers to fund the use of MDMA-based therapy to treat post-traumatic stress disorder following a landmark deal with Medibank.
Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.
Investment bank UBS expects Donald Trump’s tariff threat on pharmaceuticals to have ‘limited’ impact on biotech giant CSL, especially if plasma products are excluded.
The peak body for Australia’s life sciences industry has flagged concerns Donald Trump’s pharmaceutical tariff threat could force more local biotechs and medical technology firms to move operations overseas.
The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.
WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.
WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.
The Federal Government is pumping $1 million into WA biotech Argenica Therapeutics to advance global clinical trials for its potentially life-saving stroke drug.
